Molecular Formula | C22H39ClN2O6S |
Molar Mass | 495.07 |
Melting Point | 135-137°C |
Boling Point | 611.7℃ at 760 mmHg |
Solubility | DMSO: >12mg/mL at warmed to 60°C |
Appearance | White solid |
Color | white to beige |
Merck | 14,9464 |
Storage Condition | -20°C |
In vitro study | Tirofiban (MK-383, Aggrastat) is a non-peptide derivative of tyrosine that selectively inhibits the GP-IIb/IIIa receptor and has the lowest effect on the vβ3 Vitronectin receptor. Tirofiban inhibited gel-filtered platelet aggregation induced by 10 μm ADP with an IC50 of 9 nM, but inhibited human umbilical vein adhesion to Vitronectin with an IC50 of 62 μmol/L, this is dependent on the vβ3 receptor. |
In vivo study | Tirofiban(10 to 500 mg/kg or 10 micrograms/kg/min continuous intravenous infusion for 360 minutes) inhibits platelet aggregation with ADP and collagen in the canine model. Treatment of humans with Tirofiban at 0.15 μg/kg/min for 4 hours increased bleeding time 2.5-fold and inhibited 97% of ADP-induced platelet aggregation. |
Hazard Symbols | Xi - Irritant![]() |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S37 - Wear suitable gloves. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
WGK Germany | 3 |